Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06624644 · ClinicalTrials.gov registry record · Phase 2
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
A Phase 2 study of Cutaneous Melanoma and Unresectable Melanoma, sponsored by Linnaeus Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 7
- Study locations
NCT06624644 is a Phase 2 study of Cutaneous Melanoma and Unresectable Melanoma that is actively recruiting participants, run by Linnaeus Therapeutics. The registered enrollment target is 135 participants, below the 363-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (63% lower). The trial reports 7 study locations across 5 states.
The verdict
NCT06624644, a Phase 2 study of Cutaneous Melanoma and Unresectable Melanoma, is actively recruiting participants, sponsored by Linnaeus Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compare LNS8801 taken alone or LNS8801 taken together with another drug called pembrolizumab to other therapies as decided by the treating doctor. 135 patients will be randomly (like flipping a coin) placed in 3 treatment groups. In the first group (LNS8801 only) - Patients will take 125mg tablet of LNS8801 by mouth once per day every day for up to 2 years. In the second group (LNS8801 + pembrolizumab) - Patients will take 125mg tablet of LNS8801 by mouth once per day plus 200 mg of pembrolizumab by IV infusion once every 3 weeks for up to 2 years. In the third group, called Physician's Choice (PC), patients will receive chemotherapy (dacarbazine or temozolomide) or immunotherapy (pembrolizumab, nivolumab/relatlimab or nivolumab/ipilimumab) as determined by their treating physician. How often the patient visits the clinic visits will depend on the treatment group. Besides returning to the clinic for treatment, the patient will undergo periodic safety assessments and other required study procedures such as imaging assessments.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL LNS8801
- DRUG Chemotherapy (dacarbazine or temozolomide)
- BIOLOGICAL Immunotherapy (Pembrolizumab)
- BIOLOGICAL Immunotherapy (nivolumab and relatlimab)
Study Locations (7)
California
- USC Newport Beach - Newport Beach
- UCSF - San Francisco
- Stanford - Stanford
Colorado
- University of Colorado Anschutz - Aurora
Massachusetts
- Dana Farber - Boston
New Mexico
- University of New Mexico - Albuquerque
Pennsylvania
- UPenn - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2031-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06624644
The ClinicalTrials.gov registry entry for NCT06624644 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 363-participant average among 30 other Cutaneous Melanoma trials with a reported enrollment target (63% lower). The listed sponsor is Linnaeus Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Cutaneous Melanoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06624644 reports 7 study locations spanning 5 distinct geographic areas - top geographies include California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06624644 about?
NCT06624644 is a clinical study titled "A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma". The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Researchers will compa...
What is the current status of trial NCT06624644?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2025-08-06. Estimated completion is 2031-02.
What conditions does trial NCT06624644 study?
This clinical trial studies the following conditions: Cutaneous Melanoma, Unresectable Melanoma, Melanoma (Skin Cancer), Melanoma Stage IIIB-IV.
What interventions are being tested in trial NCT06624644?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), LNS8801 (BIOLOGICAL), Chemotherapy (dacarbazine or temozolomide) (DRUG), Immunotherapy (Pembrolizumab) (BIOLOGICAL), Immunotherapy (nivolumab and relatlimab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT06624644?
This trial is sponsored by Linnaeus Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06624644 being conducted?
This trial has 7 study locations across California, Colorado, Massachusetts, New Mexico, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cutaneous Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
RECRUITING · Phase 2
-
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
ACTIVE NOT RECRUITING · Phase 2
-
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
ACTIVE NOT RECRUITING · Phase 2
-
Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
COMPLETED · Phase 2
-
Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.